Vascular effects of Δ9-tetrahydrocannabinol (THC), anandamide and N-arachidonoyldopamine (NADA) in the rat isolated aorta

European Journal of Pharmacology

Volumn 507, Issue 1-3, 2005, Pages 211-221

  O'Sullivan, Saoirse E ^a   Kendall, David A ^a   Randall, Michael D ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Anandamide; Aorta; Cannabinoids; Endothelium; THC (Tetrahydrocannabinol); Vanilloid

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; CAPSAICIN; DOPAMINE DERIVATIVE; DRONABINOL; INDOMETACIN; N ARACHIDONOYLDOPAMINE; PERTUSSIS TOXIN; PROSTAGLANDIN SYNTHASE; RIMONABANT; UNCLASSIFIED DRUG;

ANIMAL TISSUE; AORTA; ARTERY CONSTRICTION; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; INTERMETHOD COMPARISON; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; VASODILATATION;

ANIMALS; AORTA; ARACHIDONIC ACIDS; CANNABINOIDS; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; POLYUNSATURATED ALKAMIDES; RATS; RATS, WISTAR; TETRAHYDROCANNABINOL; VASOMOTOR SYSTEM;

EID: 12344322528     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2004.11.056     Document Type: Article

References (34)

1. D.A. Andersson, M. Adner, E.D. Hogestatt, and P.M. Zygmunt Mechanisms underlying tissue selectivity of anandamide and other vanilloid receptor agonists Mol. Pharmacol. 62 2002 705 713
2. + current J. Biol. Chem. 278 2003 46188 46194
3. T. Bisogno, D. Melck, M.Yu. Bobrov, N.M. Gretskaya, V.V. Bezuglov, L. De Petrocellis, and V. Di Marzo N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo Biochem. J. 351 2000 817 824
4. E.F. Ellis, S.F. Moore, and K.A. Willoughby Anandamide and delta 9-THC dilation of cerebral arterioles is blocked by indomethacin Am. J. Physiol. 269 1995 H1859 H1864
5. F. Fan, D.R. Compton, S. Ward, L. Melvin, and B.R. Martin Development of cross-tolerance between delta 9-tetrahydrocannabinol, CP 55,940 and WIN 55,212 J. Pharmacol. Exp. Ther. 271 1994 1383 1390
6. F. Fan, Q. Tao, M. Abood, and B.R. Martin Cannabinoid receptor down-regulation without alteration of the inhibitory effect of CP 55,940 on adenylyl cyclase in the cerebellum of CP 55,940-tolerant mice Brain Res. 706 1996 13 20
7. I. Fleming, B. Schermer, R. Popp, and R. Busse Inhibition of the production of endothelium-derived hyperpolarizing factor by cannabinoid receptor agonists Br. J. Pharmacol. 126 1999 949 960
8. S.J. Gatley, A.N. Gifford, N.D. Volkow, R. Lan, and A. Makriyannis 123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors Eur. J. Pharmacol. 307 1996 331 338
9. 2+ influx Br. J. Pharmacol. 139 2003 585 597
10. W.S. Ho, and C.R. Hiley Vasorelaxation to the novel endocannabinoid virodhamine 13th International Cannabinoid Research Symposium 2003 89 (Abstract)
11. 1 receptors fail to cause relaxation, but couple via Gi/Go to the inhibition of adenylyl cyclase in carotid artery smooth muscle Br. J. Pharmacol. 128 1999 597 604
12. A.C. Howlett, F. Barth, T.I. Bonner, G. Cabral, P. Casellas, W.A. Devane, C.C. Felder, M. Herkenham, K. Mackie, B.R. Martin, R. Mechoulam, and R.G. Pertwee International Union of Pharmacology: XXVII. Classification of cannabinoid receptors Pharmacol. Rev. 54 2002 161 202
13. Z. Járai, J.A. Wagner, K. Varga, K.D. Lake, D.R. Compton, B.R. Martin, A.M. Zimmer, T.I. Bonner, N.E. Buckley, E. Mezey, R.K. Razdan, A. Zimmer, and G. Kunos Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors Proc. Natl. Acad. Sci. 96 1999 14136 14141
14. R.T. Jones Cardiovascular system effects of marijuana J. Clin. Pharmacol. 42 2002 58S 63S
15. S. Kagota, Y. Yamaguchi, K. Nakamura, T. Sugiura, K. Waku, and M. Kunitomo 2-Arachidonoylglycerol, a candidate of endothelium-derived hyperpolarizing factor Eur. J. Pharmacol. 415 2001 233 238
16. S. Mukhopadhyay, B.M. Chapnick, and A.C. Howlett Anandamide-induced vasorelaxation in rabbit aortic rings has two components: G protein dependent and independent Am. J. Physiol. 282 2002 H2046 H2054
17. H. Ninomiya, H. Otani, K. Lu, T. Uchiyama, M. Kido, and H. Imamura Enhanced IPC by activation of pertussis toxin-sensitive and -insensitive G protein-coupled purinoceptors Am. J. Physiol. 282 2002 H1933 H1943
18. L. Offertáler, F.M. Mo, S. Batkai, J. Liu, M. Begg, R.K. Razdan, B.R. Martin, R.D. Bukoski, and G. Kunos Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor Mol. Pharmacol. 63 2003 699 705
19. S.E. O'Sullivan, D.A. Kendall, and M.D. Randall Characterisation of the vasorelaxant properties of the novel endocannabinoid N-arachidonoyl-dopamine (NADA) Br. J. Pharmacol. 141 2004 803 812
20. S.E. O'Sullivan, D.A. Kendall, and M.D. Randall Heterogeneity in the mechanisms of vasorelaxation to anandamide in resistance and conduit rat mesenteric arteries Br. J. Pharmacol. 142 2004 435 442
21. 9-tetrahydrocannabinol (THC) in isolated rat mesenteric arteries. Proceedings of the British Pharmacological Society at http://www.pa2online.org/Vol2Issue2abst013P.html.
22. R.G. Pertwee Novel pharmacological targets for cannabinoids Curr. Neuropharmacol. 2 2004 9 29 (review)
23. M.D. Randall, D.A. Kendall, and S.E. O'Sullivan The complexities of the cardiovascular actions of cannabinoids Br. J. Pharmacol. 142 2004 20 26
24. M. Rinaldi-Carmona, F. Barth, M. Heaulme, D. Shire, B. Calandra, C. Congy, S. Martinez, J. Maruani, G. Neliat, and D. Caput SR141716A, a potent and selective antagonist of the brain cannabinoid receptor FEBS Lett. 350 1994 240 244
25. 2 cannabinoid receptor J. Pharmacol. Exp. Ther. 284 1998 644 650
26. F. Stanke-Labesque, M. Mallaret, B. Lefebvre, G. Hardy, F. Caron, and G. Bessard 2-Arachidonoyl glycerol induces contraction of isolated rat aorta: role of cyclooxygenase-derived products Cardiovasc. Res. 63 2004 155 160
27. P. Tep-areenan, D.A. Kendall, and M.D. Randall Mechanisms of vasorelaxation to testosterone in the rat aorta Eur. J. Pharmacol. 465 2003 125 132
28. B. Vanheel, and J. Van de Voorde Regional differences in anandamide- and methanandamide-induced membrane potential changes in rat mesenteric arteries J. Pharmacol. Exp. Ther. 296 2001 322 328
29. R. White, and C.R. Hiley The actions of some cannabinoid receptor ligands in the rat isolated mesenteric artery Br. J. Pharmacol. 125 1998 533 541
30. J.L. Wiley, and B.R. Martin Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes Chem. Phys. Lipids 121 2002 57 63
31. S. Zhuang, J. Kittler, E.V. Grigorenko, M.T. Kirby, L.J. Sim, R.E. Hampson, S.R. Childers, and S.A. Deadwyler Effects of long-term exposure to delta9-THC on expression of cannabinoid receptor (CB1) mRNA in different rat brain regions Brain Res. Mol. Brain Res. 62 1998 141 149
32. C. Zoratti, D. Kipmen-Korgun, K. Osibow, R. Malli, and W.F. Graier Anandamide initiates Ca(2+) signaling via CB2 receptor linked to phospholipase C in calf pulmonary endothelial cells Br. J. Pharmacol. 140 2003 1351 1362
33. P.M. Zygmunt, J. Petersson, D.A. Andersson, H.H. Chuang, M. Sorgard, V. DI Marzo, D. Julius, and E.D. Hogestatt Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide Nature 400 1999 452 457
34. P.M. Zygmunt, D.A. Andersson, and E.D. Hogestatt Delta 9-tetrahydrocannabinol and cannabinol activate capsaicin-sensitive sensory nerves via a CB1 and CB2 cannabinoid receptor-independent mechanism J. Neurosci. 22 2002 4720 4727